A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

NCT04641312 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug LY3457263 in both healthy volunteers and people with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 67 people

Who can join Ages 20–65 · all sexes Healthy volunteers accepted.

Timeline Started 2020-11 · est. completion 2021-12

Where 2 sites · Germany

What this study is testing ClinicalTrials.gov NCT04641312 ↗

Description as written by the study sponsor.

The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 in healthy participants and participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study has two parts (part A and B). Each part will last up to 10 weeks and may include up to either 13 (part A) or 19 (part B) visits.

Treatments tested

LY3457263 Drug

Administered SC
Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Healthy, Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04641312 ↗